Halozyme Therapeutics
HALO
#1977
Rank
$5.85 B
Marketcap
$42.01
Share price
0.44%
Change (1 day)
7.77%
Change (1 year)

P/E ratio for Halozyme Therapeutics (HALO)

P/E ratio as of October 2022 (TTM): 16.0

According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.023. At the end of 2021 the company had a P/E ratio of 14.1.

P/E ratio history for Halozyme Therapeutics from 2004 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202114.1-68.29%
202044.5-225.46%
2019-35.533.31%
2018-26.6-152.52%
201750.7-515.25%
2016-12.2-81.7%
2015-66.7279.89%
2014-17.5-14.56%
2013-20.549.95%
2012-13.7

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.